… have shown a progressive reduction in pituitary tumour volume, both in the pituitary fossa
and at the metastatic sites (figure 2). By 14 months, the pituitary tumour had reduced from 1·4 …

… to predict the efficacy of temozolomide. Recent evidence also suggests … pituitary tumors
resistant to temozolomide. In this article, the authors review the development of temozolomide, its …

… Between June 2011 and April 2019, twenty-one consecutive patients with recurrent or …
All patients had an histopathologically confirmed pituitary tumor and were previously treated …

… We report on 24 patients with aggressive pituitary tumors (16 LAPTs, 8 carcinomas) treated
with TMZ for a median of 6 months (range 1–23). Follow-up ranged from 4 to 91 months with …

… from all the patients. The criteria for classifying a pituitary adenoma as aggressive in the …
Only those who received at least 3 cycles of temozolomide were included in the study. Their …

… Recently, a limited number of aggressive pituitary adenomas and carcinomas resistant to
conventional treatment have been reported to respond to temozolomide (TMZ) therapy (Table 1…

… (APA) are rare variants of pituitary tumors for which no evidence-based treatment currently
… whether temozolomide represents an effective chemotherapeutic option for patients with PC …

… Literature review suggests that temozolomide may have a beneficial role in a subset of
cases. To understand the efficacy of temozolomide in progressive pituitary tumors, we reviewed …

… They may present initially as typical pituitary adenomas, with a delayed appearance of …
response to temozolomide in 44 patients with pituitary carcinomas or aggressive pituitary tumours …

… Table 1 shows all published case series treating 5 or more patients with TMZ for a pituitary
tumour (adenoma or carcinoma). The majority commenced TMZ because surgery, radiation …